Crowe S, Mills J
Division of Infectious Diseases, UCSF School of Medicine.
Dermatol Clin. 1988 Oct;6(4):521-37. doi: 10.1016/S0733-8635(18)30631-4.
This article has reviewed the principal antiviral agents and their application in the therapy and prevention of viral diseases. Only acyclovir, amantadine, ribavirin, zidovudine, and vidarabine have received FDA approval for therapy of systemic viral infections. Although ganciclovir, phosphonoformate, the acyclovir prodrugs, disoxaril, and the interferons are now being used only on an investigational basis, it is likely that at least some of these agents will soon be licensed. The search for more effective and safer antivirals continues, and with increasing academic and industrial interest, the prospects for this branch of chemotherapy appear promising.
本文综述了主要的抗病毒药物及其在病毒病治疗和预防中的应用。只有阿昔洛韦、金刚烷胺、利巴韦林、齐多夫定和阿糖腺苷已获得美国食品药品监督管理局（FDA）批准用于全身性病毒感染的治疗。虽然更昔洛韦、膦甲酸、阿昔洛韦前体药物、双羟丙氧甲基鸟嘌呤和干扰素目前仅在研究基础上使用，但这些药物中至少有一些可能很快会获得许可。对更有效、更安全的抗病毒药物的探索仍在继续，随着学术界和产业界兴趣的增加，化疗这一分支的前景似乎很乐观。
